Is VivoSim Labs going out of business?

VivoSim Labs, Inc. (VIVS) Fundamentals

A quick summary of the latest filed figures while the full analysis loads.

VivoSim Labs, Inc. (VIVS) scores 6 out of 100 on fundamentals, Distressed / Caution, based on SEC filing data.

Leading signal: Shares dilution YoY: 109.27% (YoY)

Five questions, kept separate

Survival - Critical

1-3 mo of estimated runway from 2026-06-30, based on $1.7M of cash and short-term investments against $10.1M of annual burn. Adjusted shares outstanding increased 109.3% over the comparison year.

Business quality - Pre-commercial

Operating margins cannot grade a pipeline; Survival and clinical evidence remain the relevant lenses here.

Trajectory - Clinical progress unavailable

Fundamentals can show funding and burn, but not whether the clinical pipeline is advancing.

Valuation - Reasonable

245.2% net-cash backing support a reasonable pre-commercial Valuation assessment.

Event risk - Evidence unavailable

No active asserted adverse event was found in the available filing evidence. The filing evidence is stale or incomplete, so this is not proof of absence.

What the rules read

• Shares dilution YoY: 109.27% (YoY)
• Debt / Equity: Negative equity (balance sheet deficit; monitor solvency)
• Cash Runway (years): 0.16y
• Revenue CAGR (3Y): -29.26%
• Revenue growth YoY: -51.35% (YoY)
• Return on Assets: -320.72%
• Cash Burn Deceleration: 45.58% QoQ improvement (Rapid improvement)
• FCF margin: -9038.39% (Inv. Mode)
• Revenue Quality: Quality concerns (DSO +12d, Rev +-51%)
• Price / Sales: 41.2x (see Valuation)
• Price / Earnings: Unprofitable (see Valuation)

Read from filings through 2026-08-12.

Price as of 2026-09-07.